Neoadjuvant Immunotherapy in Melanoma - The New Frontier.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34083235.
- Also identified by DOI 10.1158/1078-0432.CCR-21-1236.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neoadjuvant immunotherapy is gathering pace, particularly in melanoma. A recent study of pembrolizumab and HDI not only further supports the safety and activity of neoadjuvant anti-PD-1 based immunotherapy but also highlights neoadjuvant therapy as a solid platform for drug development that is likely to become a standard-of-care in the near future.<i>See related article by Najjar et al., p. 4195</i>.
Medical subject headings
- Melanoma
- Neoadjuvant Therapy